Claim your company profile
AfterRaise/Weekly/Week 2, 2026

The AfterRaise week

Week 2, 2026

56 rounds, $26.6B of announced capital. The largest: xAI raised $20.0B. Sorted by size; every figure links to its source.

FundingPublic signal9 months ago
xAI
$20.0B · Series E · USA · Other
What changed

Raised $20.0B in Series E funding.

The company said the funding supports continue to accelerate infrastructure buildout, enable the rapid development and deployment of AI products reaching billions of users, and fuel research advancing xAI's core mission to understand the universe.

Likely next AfterRaise intelligenceNew market entryFirst local hires in the new marketLocal entity and legal setup
Where help may be relevant AfterRaise intelligenceInfrastructure and computeData partnershipsProduct leadershipMarket-entry advisersLocal employment infrastructure
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
Global Technical Realty
$1.9B · Undisclosed · London, UK · AI & Data Infrastructure
What changed

Raised $1.9B.

The company said the funding supports expand operations and its development efforts.

Likely next AfterRaise intelligenceNew market entryFirst local hires in the new marketLocal entity and legal setup
Where help may be relevant AfterRaise intelligenceInfrastructure and computeSecurity reviewData partnershipsProduct leadershipMarket-entry advisers
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
Kraken
$1.0B · Undisclosed · UK · Other
What changed

Raised $1.0B, led by D1 Capital Partners.

The announcement did not set out what the funding supports.

Likely next AfterRaise intelligenceAggressive multi-front expansionSenior executive hiringOperational scale
Where help may be relevant AfterRaise intelligenceCommercial leadershipOperations hiringGo-to-market partnershipsFinance and compliance
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
Cyera
$400M · Series F · NYC, USA · AI & Data Infrastructure
What changed

Raised $400M in Series F funding.

The announcement did not set out what the funding supports.

Likely next AfterRaise intelligenceAggressive multi-front expansionSenior executive hiringOperational scale
Where help may be relevant AfterRaise intelligenceCommercial leadershipOperations hiringGo-to-market partnershipsFinance and compliance
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
Erebor Bank
$350M · Undisclosed · Columbus, USA · Fintech & Insurance
What changed

Raised $350M, led by Lux Capital.

The announcement did not set out what the funding supports.

Likely next AfterRaise intelligenceAggressive multi-front expansionSenior executive hiringOperational scale
Where help may be relevant AfterRaise intelligenceCompliance and licensingRisk managementBanking partnershipsEnterprise salesFraud prevention
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
Parabilis Medicines
$305M · Series F · Cambridge, USA · Biotech & Pharma
What changed

Raised $305M in Series F funding.

The announcement did not set out what the funding supports.

Likely next AfterRaise intelligenceResearch programme expansionScientific team growthAggressive multi-front expansion
Where help may be relevant AfterRaise intelligenceClinical operationsScientific hiringScientific advisersResearch operationsSpecialist suppliers
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
Rain
$250M · Series C · NYC, USA · Fintech & Insurance
What changed

Raised $250M in Series C funding.

The announcement did not set out what the funding supports.

Likely next AfterRaise intelligencePlatform and infrastructure scalingInfrastructure hiringAggressive multi-front expansion
Where help may be relevant AfterRaise intelligenceBanking partnershipsData securityPlatform engineeringCloud and compute partnersSecurity review
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
Soley Therapeutics
$200M · Series C · San Francisco, USA · Biotech & Pharma
What changed

Raised $200M in Series C funding.

The announcement did not set out what the funding supports.

Likely next AfterRaise intelligenceResearch programme expansionScientific team growthAggressive multi-front expansion
Where help may be relevant AfterRaise intelligenceClinical operationsScientific hiringScientific advisersResearch operationsSpecialist suppliers
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
Alveus Therapeutics
$160M · Series A · Philadelphia, USA · Biotech & Pharma
What changed

Raised $160M in Series A funding.

The announcement did not set out what the funding supports.

Likely next AfterRaise intelligenceResearch programme expansionScientific team growthAccelerated hiring across functions
Where help may be relevant AfterRaise intelligenceClinical operationsScientific hiringScientific advisersResearch operationsSpecialist suppliers
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
LMArena
$150M · Series A · San Francisco, USA · AI & Data Infrastructure
What changed

Raised $150M in Series A funding, led by Felicis and UC Investments (University of California).

The company said the funding supports expand operations and its development efforts.

Likely next AfterRaise intelligenceNew market entryFirst local hires in the new marketLocal entity and legal setup
Where help may be relevant AfterRaise intelligenceInfrastructure and computeData partnershipsProduct leadershipMarket-entry advisersLocal employment infrastructure
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
Diagonal Therapeutics
$125M · Series B · Watertown, USA · Biotech & Pharma
What changed

Raised $125M in Series B funding.

The announcement did not set out what the funding supports.

Likely next AfterRaise intelligenceRegulatory and certification milestonesCompliance team growthAggressive multi-front expansion
Where help may be relevant AfterRaise intelligenceRegulatory affairsQuality systemsScientific hiringRegulatory advisersCertification specialists
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
Corgi
$108M · Undisclosed · San Francisco, USA · Fintech & Insurance
What changed

Raised $108M.

The announcement did not set out what the funding supports.

Likely next AfterRaise intelligenceProduct launches and new tiersProduct leadership hiringAggressive multi-front expansion
Where help may be relevant AfterRaise intelligenceBanking partnershipsProduct leadershipDesign partnersSpecialist engineeringCompliance and licensing
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
EpiBiologics
$107M · Series B · San Mateo, USA · Biotech & Pharma
What changed

Raised $107M in Series B funding.

The announcement did not set out what the funding supports.

Likely next AfterRaise intelligenceAggressive multi-front expansionSenior executive hiringCommercial scale-up
Where help may be relevant AfterRaise intelligenceClinical operationsRegulatory affairsCMC and manufacturingQuality systemsMedical affairs
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
Lyte
$107M · Undisclosed · USA · Other
What changed

Raised $107M.

The company said the funding supports build the perception foundation for autonomous machines.

Likely next AfterRaise intelligenceNew market entryFirst local hires in the new marketLocal entity and legal setup
Where help may be relevant AfterRaise intelligenceInfrastructure and computeData partnershipsProduct leadershipMarket-entry advisersLocal employment infrastructure
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
Rakuten Medical
$100M · Series F · San Diego, USA · Biotech & Pharma
What changed

Raised $100M in Series F funding.

The announcement did not set out what the funding supports.

Likely next AfterRaise intelligenceProduct launches and new tiersProduct leadership hiringCommercial team build-out
Where help may be relevant AfterRaise intelligenceScientific hiringLicensing and BD partnershipsProduct leadershipDesign partnersSpecialist engineering
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
Swap
$100M · Series C · NYC, USA · Enterprise Software
What changed

Raised $100M in Series C funding, led by DST Global and ICONIQ.

The company said the funding supports continue to expand operations and its business reach, as well as to invest in digital payments and in monetizing transactions.

Likely next AfterRaise intelligenceNew market entryFirst local hires in the new marketLocal entity and legal setup
Where help may be relevant AfterRaise intelligenceCloud infrastructureChannel partnershipsMarket-entry advisersLocal employment infrastructureIn-market partnerships
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
Cambium
$100M · Series B · El Segundo, USA · Defence, Space & Aerospace
What changed

Raised $100M in Series B funding, led by 8VC.

The company said the funding supports accelerate both its product pipeline and materials manufacturing in the U.S. and Europe, supporting customers across aerospace, defense, energy, marine, motorsport, and other high-performance sectors.

Likely next AfterRaise intelligenceProduct launches and new tiersProduct leadership hiringResearch programme expansion
Where help may be relevant AfterRaise intelligenceCertification and airworthinessManufacturing scale-upProduct leadershipDesign partnersSpecialist engineering
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
FineHeart
€83M · Series C · France · Other
What changed

Raised €83M in Series C funding, led by Arnaud Mascarell.

The announcement did not set out what the funding supports.

Likely next AfterRaise intelligenceAccelerated hiring across functionsMulti-market operationsExecutive appointments
Where help may be relevant AfterRaise intelligenceCommercial leadershipOperations hiringGo-to-market partnershipsFinance and compliance
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
Pomelo Care
$92M · Series C · NYC-based developer of evidence, USA · Healthcare & Medtech
What changed

Raised $92M in Series C funding.

The announcement did not set out what the funding supports.

Likely next AfterRaise intelligenceAccelerated hiring across functionsMulti-market operationsExecutive appointments
Where help may be relevant AfterRaise intelligenceClinical evidenceRegulatory affairsReimbursement and market accessHospital procurement experienceQuality systems
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
Apella
$80M · Series B · San Francisco, USA · Healthcare & Medtech
What changed

Raised $80M in Series B funding.

The announcement did not set out what the funding supports.

Likely next AfterRaise intelligenceAccelerated hiring across functionsCommercial scale-upNew market preparation
Where help may be relevant AfterRaise intelligenceClinical evidenceRegulatory affairsReimbursement and market accessHospital procurement experienceQuality systems
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
Corsera Health
$80M · Series A · Boston, USA · Biotech & Pharma
What changed

Raised $80M in Series A funding.

The announcement did not set out what the funding supports.

Likely next AfterRaise intelligenceResearch programme expansionScientific team growthAccelerated hiring across functions
Where help may be relevant AfterRaise intelligenceClinical operationsScientific hiringScientific advisersResearch operationsSpecialist suppliers
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
Mediar Therapeutics
$76M · Series B · Boston, USA · Biotech & Pharma
What changed

Raised $76M in Series B funding, led by Amplitude Ventures and ICG.

The company said the funding supports further advance its wholly owned assets, including MTX-474, an antagonist of EphrinB2, being studied in a Phase 2a study in patients with systemic sclerosis (SSc), and MTX-439, a SMOC2 antagonist, proceeding to Phase 1 studies for the treatment of chronic kidney disease (CKD) associated fibrosis.

Likely next AfterRaise intelligenceResearch programme expansionScientific team growthAccelerated hiring across functions
Where help may be relevant AfterRaise intelligenceClinical operationsScientific hiringScientific advisersResearch operationsSpecialist suppliers
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
Spiro Medical
$67M · Series A · Irvine, USA · Healthcare & Medtech
What changed

Raised $67M in Series A funding.

The announcement did not set out what the funding supports.

Likely next AfterRaise intelligenceAccelerated hiring across functionsRepeatable go-to-market buildFirst senior commercial hires
Where help may be relevant AfterRaise intelligenceClinical evidenceRegulatory affairsReimbursement and market accessHospital procurement experienceQuality systems
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
Valinor Enterprises
$54M · Series A · Washington, USA · Defence, Space & Aerospace
What changed

Raised $54M in Series A funding.

The announcement did not set out what the funding supports.

Likely next AfterRaise intelligenceAccelerated hiring across functionsRepeatable go-to-market buildFirst senior commercial hires
Where help may be relevant AfterRaise intelligenceCertification and airworthinessGovernment relationsSecurity clearance hiringManufacturing scale-upSupply chain
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
Poplar Therapeutics
$50M · Series A · Boston, USA · Biotech & Pharma
What changed

Raised $50M in Series A funding.

The announcement did not set out what the funding supports.

Likely next AfterRaise intelligenceResearch programme expansionScientific team growthAccelerated hiring across functions
Where help may be relevant AfterRaise intelligenceClinical operationsScientific hiringScientific advisersResearch operationsSpecialist suppliers
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
Vizgen
$48M · Undisclosed · Waltham, USA · Other
What changed

Raised $48M.

The announcement did not set out what the funding supports.

Likely next AfterRaise intelligenceAccelerated hiring across functionsOperational scaleMarket consolidation
Where help may be relevant AfterRaise intelligenceCommercial leadershipOperations hiringGo-to-market partnershipsFinance and compliance
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
GSME
$35M · Series B · San Jose, USA · Semiconductors & Hardware
What changed

Raised $35M in Series B funding, led by Maverick Silicon.

The company said the funding supports accelerate R&D, expand its platform development, and support strategic acquisitions and hiring.

Likely next AfterRaise intelligenceTeam growth across core functionsSenior leadership appointmentsNew market entry
Where help may be relevant AfterRaise intelligenceHardware engineeringIndustrial partnershipsExecutive searchTalent partnersEmployer infrastructure
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
Protege
$30M · Series A · NYC, USA · AI & Data Infrastructure
What changed

Raised $30M in Series A funding.

The announcement did not set out what the funding supports.

Likely next AfterRaise intelligenceProduct launches and new tiersProduct leadership hiringAccelerated hiring across functions
Where help may be relevant AfterRaise intelligenceData partnershipsProduct leadershipDesign partnersSpecialist engineeringInfrastructure and compute
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
Enable Injections
$30M · Series C · Cincinnati, USA · Healthcare & Medtech
What changed

Raised $30M in Series C funding, led by Magnetar Capital.

The company said the funding supports consolidate its supply chain capabilities, and drive commercial growth.

Likely next AfterRaise intelligenceCommercial team build-outRevenue leadership appointmentsManufacturing capacity expansion
Where help may be relevant AfterRaise intelligenceQuality systemsClinical hiringProvider partnershipsRevenue leadershipChannel partners
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
Blackbird.AI
$28M · Undisclosed · NYC, USA · AI & Data Infrastructure
What changed

Raised $28M.

The announcement did not set out what the funding supports.

Likely next AfterRaise intelligenceAccelerated hiring across functionsOperational scaleMarket consolidation
Where help may be relevant AfterRaise intelligenceInfrastructure and computeAI governanceEnterprise salesSecurity reviewModel evaluation
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
Flywheel
$25M · Undisclosed · Minneapolis, USA · Healthcare & Medtech
What changed

Raised $25M.

The announcement did not set out what the funding supports.

Likely next AfterRaise intelligenceProduct launches and new tiersProduct leadership hiringAccelerated hiring across functions
Where help may be relevant AfterRaise intelligenceProvider partnershipsProduct leadershipDesign partnersSpecialist engineeringClinical evidence
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
Enodia Therapeutics
€21M · Seed · Paris, France · Biotech & Pharma
What changed

Raised €21M in Seed funding, led by Elaia.

The company said the funding supports the advancement of its small-molecule approach to modulating the SEC61 translocon, with machine learning enabling greater selectivity in targeted protein degradation than previous approaches.

Likely next AfterRaise intelligenceFounding team growthFirst commercial motion
Where help may be relevant AfterRaise intelligenceClinical operationsRegulatory affairsCMC and manufacturingQuality systemsMedical affairs
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
Qualinx
€20M · Series B · Delft, Netherlands · Semiconductors & Hardware
What changed

Raised €20M in Series B funding, led by Invest‑NL.

The company said the funding supports accelerate growth to scale mass production of its market-ready QLX3Gx Series GNSS chip and fulfill demand from global OEMs across consumer electronics, including wearables, pet trackers, IoT, drones and UAVs, vehicle and asset tracking, telecommunications, satellites and more.

Likely next AfterRaise intelligenceProduct launches and new tiersProduct leadership hiringManufacturing capacity expansion
Where help may be relevant AfterRaise intelligenceCertificationHardware engineeringIndustrial partnershipsProduct leadershipDesign partners
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
I-care
€20M · Undisclosed · Mons, Belgium · Healthcare & Medtech
What changed

Raised €20M, led by Fabrice Brion.

The company said the funding supports accelerate its growth in order to increase its market share, with plans to launch an initial public offering (postponed last spring).

Likely next AfterRaise intelligenceProduct launches and new tiersProduct leadership hiringOperational scale
Where help may be relevant AfterRaise intelligenceProvider partnershipsProduct leadershipDesign partnersSpecialist engineeringClinical evidence
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
Biller Genie
$22M · Series B · Orlando, USA · Robotics & Manufacturing
What changed

Raised $22M in Series B funding.

The announcement did not set out what the funding supports.

Likely next AfterRaise intelligenceProduct launches and new tiersProduct leadership hiringPlatform and infrastructure scaling
Where help may be relevant AfterRaise intelligenceEngineering hiringDistribution partnersIndustrial partnershipsProduct leadershipDesign partners
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
Canopy
$22M · Series B · San Francisco, USA · Healthcare & Medtech
What changed

Raised $22M in Series B funding.

The announcement did not set out what the funding supports.

Likely next AfterRaise intelligenceProduct launches and new tiersProduct leadership hiringCommercial scale-up
Where help may be relevant AfterRaise intelligenceProvider partnershipsProduct leadershipDesign partnersSpecialist engineeringClinical evidence
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
Luxury Presence
$22M · Series C · Austin, USA · Fintech & Insurance
What changed

Raised $22M in Series C funding.

The announcement did not set out what the funding supports.

Likely next AfterRaise intelligenceProduct launches and new tiersProduct leadership hiringMulti-market operations
Where help may be relevant AfterRaise intelligenceBanking partnershipsProduct leadershipDesign partnersSpecialist engineeringCompliance and licensing
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
Luminate
$21M · Series A · Galway, Ireland · Healthcare & Medtech
What changed

Raised $21M in Series A funding, led by ARTIS Ventures and Lachy Groom.

The company said the funding supports launch access to home cancer care at 40 partner oncology clinics before launching its new patient-led home infusion technology in mid-2026.

Likely next AfterRaise intelligenceProduct launches and new tiersProduct leadership hiringCommercial and distribution partnerships
Where help may be relevant AfterRaise intelligenceProvider partnershipsProduct leadershipDesign partnersSpecialist engineeringPartnership leadership
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
Tucuvi
$20M · Series A · Madrid, Spain · Healthcare & Medtech
What changed

Raised $20M in Series A funding, led by Cathay Innovation and Kibo Ventures.

The company said the funding supports accelerate international expansion, particularly in the United Kingdom and United States, and enhance its AI technology to manage more complex clinical use cases.

Likely next AfterRaise intelligenceGlobal market entryUK market entryUS market entry
Where help may be relevant AfterRaise intelligenceProvider partnershipsMarket-entry advisersLocal employment infrastructureIn-market partnershipsProduct leadership
Approach preferences not yet specified
Company pageSource
FundingPublic signal9 months ago
Prudentia Sciences
$20M · Series A · Cambridge, USA · AI & Data Infrastructure
What changed

Raised $20M in Series A funding.

The announcement did not set out what the funding supports.

Likely next AfterRaise intelligenceRepeatable go-to-market buildFirst senior commercial hires
Where help may be relevant AfterRaise intelligenceInfrastructure and computeAI governanceEnterprise salesSecurity reviewModel evaluation
Approach preferences not yet specified
Company pageSource

The Daily Brief

This page, in your inbox.

Every disclosed US, UK and European round of $5M or more, with what each company said the money supports, the morning it is observed. One email, only on days something happened, unsubscribe with one click.